FibroGen Balance Sheet Health
Financial Health criteria checks 1/6
FibroGen has a total shareholder equity of $-201.7M and total debt of $91.0M, which brings its debt-to-equity ratio to -45.1%. Its total assets and total liabilities are $264.4M and $466.1M respectively.
Key information
-45.1%
Debt to equity ratio
US$90.98m
Debt
| Interest coverage ratio | n/a |
| Cash | US$131.00m |
| Equity | -US$201.70m |
| Total liabilities | US$466.12m |
| Total assets | US$264.42m |
Recent financial health updates
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Feb 13
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Oct 09Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Jul 06Recent updates
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 26% Share Price Rise
Dec 25Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding
Oct 29The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%
Aug 19Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding
Jul 04FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward
Jun 06Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains
May 28Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet
May 07FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Mar 22There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise
Feb 05FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%
Dec 22A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)
Nov 24Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)
Apr 18Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Feb 13The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts
Nov 12Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
Oct 09FibroGen completes patient enrollment for Roxadustat to treat anemia in patients
Aug 26FibroGen Q2 2022 Earnings Preview
Aug 05Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Jul 06Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?
Mar 31Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook
Mar 05Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?
Dec 08Financial Position Analysis
Short Term Liabilities: FGEN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: FGEN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: FGEN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: FGEN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FGEN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FGEN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 32.5% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 00:40 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
FibroGen, Inc. is covered by 14 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Kennen MacKay | Credit Suisse |
| Matthew Keller | H.C. Wainwright & Co. |